JP2022514254A5 - - Google Patents
Info
- Publication number
- JP2022514254A5 JP2022514254A5 JP2021534201A JP2021534201A JP2022514254A5 JP 2022514254 A5 JP2022514254 A5 JP 2022514254A5 JP 2021534201 A JP2021534201 A JP 2021534201A JP 2021534201 A JP2021534201 A JP 2021534201A JP 2022514254 A5 JP2022514254 A5 JP 2022514254A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781242P | 2018-12-18 | 2018-12-18 | |
| US62/781,242 | 2018-12-18 | ||
| PCT/IB2019/060957 WO2020128861A1 (en) | 2018-12-18 | 2019-12-17 | Rapamycin derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514254A JP2022514254A (ja) | 2022-02-10 |
| JP2022514254A5 true JP2022514254A5 (https=) | 2022-12-26 |
| JP7618553B2 JP7618553B2 (ja) | 2025-01-21 |
Family
ID=69165426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534201A Active JP7618553B2 (ja) | 2018-12-18 | 2019-12-17 | ラパマイシン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12281125B2 (https=) |
| EP (1) | EP3898637B1 (https=) |
| JP (1) | JP7618553B2 (https=) |
| KR (1) | KR20210105397A (https=) |
| CN (1) | CN113260619B (https=) |
| AU (1) | AU2019409366B2 (https=) |
| BR (1) | BR112021011325A2 (https=) |
| CA (1) | CA3122922A1 (https=) |
| DK (1) | DK3898637T3 (https=) |
| ES (1) | ES3014225T3 (https=) |
| FI (1) | FI3898637T3 (https=) |
| HR (1) | HRP20250197T1 (https=) |
| HU (1) | HUE070859T2 (https=) |
| LT (1) | LT3898637T (https=) |
| MX (1) | MX2021007247A (https=) |
| PL (1) | PL3898637T3 (https=) |
| PT (1) | PT3898637T (https=) |
| RS (1) | RS66527B1 (https=) |
| SI (1) | SI3898637T1 (https=) |
| WO (1) | WO2020128861A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| IL285067B2 (en) | 2019-01-22 | 2025-02-01 | Aeovian Pharmaceuticals Inc | MTORC Modulators and Their Uses |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| EP4688148A1 (en) * | 2023-04-07 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Selective rapamycin analogs and uses thereof |
| GB202415232D0 (en) | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| WO1996041865A1 (en) * | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| DE69637641D1 (de) | 1995-06-07 | 2008-09-25 | Ariad Gene Therapeutics Inc | Auf rapamycin basierende regulation biologischer vorgänge |
| US5985890A (en) | 1995-06-09 | 1999-11-16 | Novartis Ag | Rapamycin derivatives |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| CA2257803C (en) | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| JP2002508971A (ja) | 1998-01-15 | 2002-03-26 | アリアド・ジーン・セラピューティクス・インコーポレーテッド | 多量体キメラ蛋白質を使用する生物学的イベントの調節 |
| ATE264863T1 (de) | 1999-08-24 | 2004-05-15 | Ariad Gene Therapeutics Inc | 28-epirapaloge |
| MX368013B (es) | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| GB0601406D0 (en) | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| US20090023768A1 (en) | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| WO2008022256A2 (en) | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| EP2670758B1 (en) | 2011-02-04 | 2022-09-28 | Synthon BV | Process for making trisubstituted silyloxyethyl triflates |
| CN103391780B (zh) | 2011-02-16 | 2015-08-19 | 诺瓦提斯公司 | 用于治疗神经变性疾病的治疗剂的组合物 |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| EP3109250A1 (en) | 2015-06-23 | 2016-12-28 | Synbias Pharma AG | Method for the synthesis of rapamycin derivatives |
| US10683308B2 (en) | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| WO2018204416A1 (en) | 2017-05-02 | 2018-11-08 | Revolution Medicines, Inc. | Rapamycin analogs as mtor inhibitors |
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| US20220202787A1 (en) | 2019-03-26 | 2022-06-30 | Novartis Ag | Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof |
-
2019
- 2019-12-17 HR HRP20250197TT patent/HRP20250197T1/hr unknown
- 2019-12-17 LT LTEPPCT/IB2019/060957T patent/LT3898637T/lt unknown
- 2019-12-17 MX MX2021007247A patent/MX2021007247A/es unknown
- 2019-12-17 HU HUE19836546A patent/HUE070859T2/hu unknown
- 2019-12-17 BR BR112021011325A patent/BR112021011325A2/pt unknown
- 2019-12-17 JP JP2021534201A patent/JP7618553B2/ja active Active
- 2019-12-17 CN CN201980087363.4A patent/CN113260619B/zh active Active
- 2019-12-17 KR KR1020217022532A patent/KR20210105397A/ko active Pending
- 2019-12-17 CA CA3122922A patent/CA3122922A1/en active Pending
- 2019-12-17 PL PL19836546.2T patent/PL3898637T3/pl unknown
- 2019-12-17 WO PCT/IB2019/060957 patent/WO2020128861A1/en not_active Ceased
- 2019-12-17 AU AU2019409366A patent/AU2019409366B2/en active Active
- 2019-12-17 US US17/414,696 patent/US12281125B2/en active Active
- 2019-12-17 SI SI201930897T patent/SI3898637T1/sl unknown
- 2019-12-17 FI FIEP19836546.2T patent/FI3898637T3/fi active
- 2019-12-17 ES ES19836546T patent/ES3014225T3/es active Active
- 2019-12-17 DK DK19836546.2T patent/DK3898637T3/da active
- 2019-12-17 EP EP19836546.2A patent/EP3898637B1/en active Active
- 2019-12-17 PT PT198365462T patent/PT3898637T/pt unknown
- 2019-12-17 RS RS20250163A patent/RS66527B1/sr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514254A5 (https=) | ||
| JP2022527270A5 (https=) | ||
| JP2020535134A5 (https=) | ||
| JP2020502047A5 (https=) | ||
| JP6964096B2 (ja) | ３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類 | |
| HRP20250197T1 (hr) | Derivati rapamicina | |
| HRP20240199T1 (hr) | Derivati rapamicina | |
| JP2021523113A5 (https=) | ||
| US10414732B2 (en) | Polymorphic compounds and uses thereof | |
| JP2020189879A5 (https=) | ||
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP2014525426A5 (https=) | ||
| JP2016515119A5 (https=) | ||
| JP2017505784A5 (https=) | ||
| JP2007512283A5 (https=) | ||
| HRP20240633T1 (hr) | Izotiazolidin 1,1-dioksid i 1,4-butan sulton derivati rapamicina i njihova uporaba | |
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2009532429A5 (https=) | ||
| JP2019504899A5 (https=) | ||
| JP2014525427A5 (https=) | ||
| JP6407955B2 (ja) | クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法 | |
| JP2014512406A5 (https=) | ||
| JP2014503574A5 (https=) | ||
| JP2021105002A5 (https=) | ||
| JP2022501429A5 (https=) |